AR004676A1 - Un derivado de la sal metanosulfonato de (1s, 2s)-1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-il)-1-propanol, una composicion farmaceutica que lo comprende y metodos para fabricar un medicamento - Google Patents

Un derivado de la sal metanosulfonato de (1s, 2s)-1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-il)-1-propanol, una composicion farmaceutica que lo comprende y metodos para fabricar un medicamento

Info

Publication number
AR004676A1
AR004676A1 ARP960103904A AR10390496A AR004676A1 AR 004676 A1 AR004676 A1 AR 004676A1 AR P960103904 A ARP960103904 A AR P960103904A AR 10390496 A AR10390496 A AR 10390496A AR 004676 A1 AR004676 A1 AR 004676A1
Authority
AR
Argentina
Prior art keywords
phenylpiperidin
propanol
hydroxy
methods
pharmaceutical composition
Prior art date
Application number
ARP960103904A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR004676A1 publication Critical patent/AR004676A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

El trihidrato de la sal metanosulfonato de (1S,2S)-1-(4-hidroxifenil)-2- (4-hidroxi-4-fenilpiperidin-1-il)-1-propanol. La invención se refiere tambien auna composicion farmaceutica para el tratamiento de enfermedades que incluye una cantidadde dicho compuesto que es eficaz en el tratamiento de cadaenfermedad y un vehiculo farmaceuticamente aceptable y a metodos para el tratamiento de enfermedades con dicho compuesto.
ARP960103904A 1995-08-11 1996-08-07 Un derivado de la sal metanosulfonato de (1s, 2s)-1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-il)-1-propanol, una composicion farmaceutica que lo comprende y metodos para fabricar un medicamento AR004676A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US223895P 1995-08-11 1995-08-11

Publications (1)

Publication Number Publication Date
AR004676A1 true AR004676A1 (es) 1999-03-10

Family

ID=21699847

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960103904A AR004676A1 (es) 1995-08-11 1996-08-07 Un derivado de la sal metanosulfonato de (1s, 2s)-1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-il)-1-propanol, una composicion farmaceutica que lo comprende y metodos para fabricar un medicamento

Country Status (41)

Country Link
US (1) US6008233A (es)
EP (1) EP0843661B1 (es)
JP (1) JP3099072B2 (es)
KR (1) KR100291882B1 (es)
CN (2) CN1198739A (es)
AP (1) AP755A (es)
AR (1) AR004676A1 (es)
AT (1) ATE215072T1 (es)
AU (1) AU710984B2 (es)
BG (1) BG63678B1 (es)
BR (1) BR9610766A (es)
CA (1) CA2228752C (es)
CO (1) CO4750830A1 (es)
CZ (1) CZ296236B6 (es)
DE (1) DE69620191T2 (es)
DK (1) DK0843661T3 (es)
DZ (1) DZ2083A1 (es)
ES (1) ES2170857T3 (es)
GT (1) GT199600051A (es)
HR (1) HRP960372B1 (es)
HU (1) HUP9802862A3 (es)
IL (1) IL122649A (es)
IS (1) IS1945B (es)
MA (1) MA23957A1 (es)
NO (1) NO310458B1 (es)
NZ (1) NZ309134A (es)
OA (1) OA10664A (es)
PE (1) PE4898A1 (es)
PL (1) PL185603B1 (es)
PT (1) PT843661E (es)
RO (1) RO120134B1 (es)
RS (1) RS49521B (es)
RU (1) RU2140910C1 (es)
SA (1) SA96170171B1 (es)
SK (1) SK284209B6 (es)
TN (1) TNSN96104A1 (es)
TR (1) TR199800208T1 (es)
TW (1) TW495502B (es)
UA (1) UA59341C2 (es)
WO (1) WO1997007098A1 (es)
ZA (1) ZA966760B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ284852A (en) * 1994-08-18 1998-06-26 Pfizer 3-(piperidin-1-yl)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidin-1-yl) alkanol derivatives; medicaments; used as a neuroprotective agent
ES2170857T3 (es) * 1995-08-11 2002-08-16 Pfizer Metanosulfonato de (1s,2s)-1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-1-il)-1-propanol trihidrato.
GB9820405D0 (en) * 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
AU3676100A (en) * 1999-04-09 2000-11-14 Mochida Pharmaceutical Co., Ltd. Remedies for neuropathic pain
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
US6620830B2 (en) * 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
YU27801A (sh) * 2000-04-28 2003-04-30 Pfizer Products Inc. Postupak za dobijanje trihidrata mezilatne soli 1-(4- hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanola i korisnih intermedijera
YU27701A (sh) * 2000-04-28 2003-04-30 Pfizer Products Inc. Postupak za dobijanje trihidrata mezilatne soli 1-(4- hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)1-propanola
AU8339301A (en) 2000-08-16 2002-02-25 Upjohn Co Compounds for the treatment of addictive disorders
EP1186303A3 (en) * 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
IL145584A0 (en) 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
UA73619C2 (en) * 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
BRPI0213393B8 (pt) * 2001-10-19 2021-05-25 Fujifilm Toyama Chemical Co Ltd derivados de éter alquílico, ou um de seus sais, processo para produzir um derivado de éter alquílico, derivado de alquil-amida, ou um de seus sais, e, composição farmacêutica
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
CN103936690B (zh) 2005-10-25 2016-06-08 盐野义制药株式会社 氨基二氢噻嗪衍生物
EP2147914B1 (en) 2007-04-24 2014-06-04 Shionogi&Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
ES2738123T3 (es) 2008-06-13 2020-01-20 Shionogi & Co Derivado heterocíclico que contiene azufre que tiene actividad inhibitoria de ß-secretasa
JPWO2010047372A1 (ja) 2008-10-22 2012-03-22 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体
BR112012013854A2 (pt) 2009-12-11 2019-09-24 Shionogi & Co derivados de oxazina.
JP5766198B2 (ja) 2010-10-29 2015-08-19 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
US8927721B2 (en) 2010-10-29 2015-01-06 Shionogi & Co., Ltd. Naphthyridine derivative
US8883779B2 (en) 2011-04-26 2014-11-11 Shinogi & Co., Ltd. Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them
WO2014065434A1 (en) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
KR102569031B1 (ko) 2014-09-15 2023-08-22 뤼겐 홀딩스 (케이맨) 리미티드 Nr2b nmda 수용체 길항제로서의 피롤로피리미딘 유도체
EP3197440A4 (en) * 2014-09-22 2018-04-18 Rugen Holdings (Cayman) Limited Treatment of anxiety disorders and autism spectrum disorders
US10221182B2 (en) 2015-02-04 2019-03-05 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists
JP6876625B2 (ja) 2015-06-01 2021-05-26 リューゲン ホールディングス （ケイマン） リミテッド Ｎｒ２ｂｎｍｄａレセプターアンタゴニストとしての３，３−ジフルオロピペリジンカルバメート複素環式化合物
EP3544610A1 (en) 2016-11-22 2019-10-02 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) * 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
WO1990014087A1 (en) * 1989-05-17 1990-11-29 Pfizer Inc. 2-piperidino-1-alkanol derivatives as antiischemic agents
NZ284852A (en) * 1994-08-18 1998-06-26 Pfizer 3-(piperidin-1-yl)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidin-1-yl) alkanol derivatives; medicaments; used as a neuroprotective agent
ES2170857T3 (es) * 1995-08-11 2002-08-16 Pfizer Metanosulfonato de (1s,2s)-1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-1-il)-1-propanol trihidrato.

Also Published As

Publication number Publication date
AU5908496A (en) 1997-03-12
TW495502B (en) 2002-07-21
NZ309134A (en) 1999-09-29
BR9610766A (pt) 1999-07-13
AU710984B2 (en) 1999-10-07
IL122649A0 (en) 1998-08-16
GT199600051A (es) 1997-12-26
CA2228752A1 (en) 1997-02-27
CN1615861A (zh) 2005-05-18
HRP960372B1 (en) 2003-04-30
WO1997007098A1 (en) 1997-02-27
SK16698A3 (en) 1999-06-11
EP0843661A1 (en) 1998-05-27
RU2140910C1 (ru) 1999-11-10
RS49521B (sr) 2006-10-27
DE69620191T2 (de) 2002-07-18
IS1945B (is) 2004-08-13
DE69620191D1 (de) 2002-05-02
HRP960372A2 (en) 1998-04-30
CA2228752C (en) 2002-12-10
PT843661E (pt) 2002-07-31
CN1198739A (zh) 1998-11-11
PL325050A1 (en) 1998-07-06
MX9801149A (es) 1998-05-31
MA23957A1 (fr) 1997-04-01
NO980574L (no) 1998-02-10
NO310458B1 (no) 2001-07-09
EP0843661B1 (en) 2002-03-27
RO120134B1 (ro) 2005-09-30
CO4750830A1 (es) 1999-03-31
JP3099072B2 (ja) 2000-10-16
BG102289A (en) 1998-09-30
AP9600856A0 (en) 1996-10-31
JPH10510552A (ja) 1998-10-13
CZ296236B6 (cs) 2006-02-15
US6008233A (en) 1999-12-28
OA10664A (en) 2000-11-06
TNSN96104A1 (fr) 2005-03-15
PE4898A1 (es) 1998-03-16
SA96170171B1 (ar) 2006-05-20
CZ39098A3 (cs) 1999-02-17
IL122649A (en) 2001-08-26
BG63678B1 (bg) 2002-09-30
DK0843661T3 (da) 2002-07-22
UA59341C2 (uk) 2003-09-15
NO980574D0 (no) 1998-02-10
PL185603B1 (pl) 2003-06-30
HUP9802862A3 (en) 1999-05-28
HUP9802862A2 (hu) 1999-04-28
SK284209B6 (en) 2004-11-03
ES2170857T3 (es) 2002-08-16
KR19990036321A (ko) 1999-05-25
IS4643A (is) 1997-12-30
ZA966760B (en) 1998-02-09
ATE215072T1 (de) 2002-04-15
YU46196A (sh) 1999-07-28
AP755A (en) 1999-08-02
DZ2083A1 (fr) 2002-10-23
TR199800208T1 (es) 1998-05-21
KR100291882B1 (ko) 2001-10-26

Similar Documents

Publication Publication Date Title
AR004676A1 (es) Un derivado de la sal metanosulfonato de (1s, 2s)-1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-il)-1-propanol, una composicion farmaceutica que lo comprende y metodos para fabricar un medicamento
PT730864E (pt) Medicamento para tratar doencas inflamatorias cardiacas
ES2181868T3 (es) Composicion farmaceutica para compuestos de piperidinoalcanol.
ES2062392T3 (es) Medicamentos que comprenden salmeterol y fluticasona.
BR9909277A (pt) Compostos com atividade em receptores muscarìnicos
RU94041223A (ru) Средство для лечения мотонейроновых заболеваний
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
AR028504A2 (es) Combinacion, metodo para mejorar la apariencia corporal de un mamifero, composicion farmaceutica, uso de dicha combinacion para la preparacion de un medicamento para la prevencion, demora de progreso, o tratamiento de desordenes metabolicos, y paquete comercial
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
RU2220723C2 (ru) Средство и способ лечения или профилактики артериосклероза
BR9607965A (pt) Composto composição farmacêutica e processo para tratar uma doença parasítica em um mamífero
BR9916114A (pt) Uso de apomorfina na fabricação de um medicamento para tratamento de disfunção erétil orgânica masculina
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
ES2189252T3 (es) Composiciones analgesicas que comprenden un antagonista de la colecistoquinina y un opioide.
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
CO5050328A1 (es) Sistema solvente para la mejor penetracion de compuestos farmaceuticos
IT1269185B (it) Associazione dotata di effetto sinergico che ha un effetto antagonista dei recettori nk1 e nk2
CY1105545T1 (el) Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας
CO5060499A1 (es) Metodos y composiciones para el tratamiento de enfermedad de reflujo gastroesofagico
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida
RU97120700A (ru) Новое фармакологическое применение антагонистов a-ii рецептора
AR002191A1 (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion, procedimiento para su preparacion
CO5590922A2 (es) Uso de istradefilina (kw-6002) para el tratamiento de trastornos de la conducta
PT768083E (pt) Sertralina para o tratamento de doentes pos-enfarte miocardico

Legal Events

Date Code Title Description
FB Suspension of granting procedure